12:00 AM
 | 
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Galaczym regulatory update

FDA granted Orphan Drug designation for Galaczym from Zymenex's Ace Biosciences A/S subsidiary to treat globoid cell...

Read the full 62 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >